The FDA has approved Danziten™, a nilotinib formulation with no mealtime restrictions, for the treatment of adults with newly diagnosed Ph+ CML-CP and resistant or intolerant Ph+ CML-CP and CML-AP.

In the non-hyperlipidemia group, patients receiving nilotinib were significantly more likely to develop CVD than those treated with imatinib (IRR, 3.21).

WESTON, Fla., May 27, 2025 /CNW/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity. Apotex Inc ...

Since starting nilotinib—known by the brand name Tasigna, one of the many approved TKI drugs—the man's hair had changed color. This change is believed to be a side effect of nilotinib.

The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only nilotinib formulation that does not require mealtime restrictions, to ...

Patients with chronic myeloid leukemia who have attained sustained deep molecular response with second-line nilotinib therapy can achieve treatment-free remission for 48 weeks or longer, according ...

The Food and Drug Administration (FDA) approved Danziten, a formulation of nilotinib, that requires no mealtime restrictions for adults with newly diagnosed Philadelphia chromosome-positive chronic ...

The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten) for chronic myeloid leukemia (CML), making this version of the tyrosine kinase inhibitor (TKI) the only one ...

In a study of 43 DLB patients, nilotinib improved cognition scores by 2.8 points versus placebo (P=0.037) on the Alzheimer's Disease Assessment Scale-Cognitive Subscale 14 (ADAS-Cog14) at 3 months ...

Nilotinib Medication Information. Discover comprehensive details about Nilotinib, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or ...